簡要描述:Illumina公司 實(shí)現(xiàn)生物信息的采集、分析和應(yīng)用,來改善人類健康。上海易匯生物科技有限公司于17年正式銷售Illumina公司基因芯片、二代測(cè)序NGS測(cè)序儀及相關(guān)測(cè)序試劑盒等產(chǎn)品Illumina/NextSeq 500/550 High Output v2 kit (75 cycles)/FC-404-2005/1 EaIllumina 測(cè)序試劑盒 FC-404-2005
詳細(xì)介紹
品牌 | illumina/美國因美納 | 貨號(hào) | FC-404-2005 |
---|---|---|---|
規(guī)格 | 1 kit | 供貨周期 | 兩周 |
主要用途 | 小型全基因組測(cè)序 組合試劑 試劑盒 | 應(yīng)用領(lǐng)域 | 醫(yī)療衛(wèi)生,化工,生物產(chǎn)業(yè),制藥 |
Illumina 測(cè)序試劑盒 FC-404-2005
Illumina/NextSeq 500/550 High Output v2 kit (75 cycles)/FC-404-2005/1 Ea
產(chǎn)品編號(hào): FC-404-2005
美 元 價(jià): $1450.00
品 牌: Illumina
產(chǎn) 地: 美國
公 司: Illumina, Inc.
產(chǎn)品分類: 分子類>二代測(cè)序>簇生成和測(cè)序試劑
公司分類: Cluster Generation & Sequencing Reagents
Illumina公司創(chuàng)立于1998年4月,是遺傳變異和生物學(xué)功能分析領(lǐng)域的優(yōu)秀的產(chǎn)品、技術(shù)和服務(wù)供應(yīng)商。通過幫助客戶加快實(shí)現(xiàn)生物信息的采集、分析和應(yīng)用,來改善人類健康。
Sequencing Kits/ Microarray Kits/Informatics Products/ Clinical Research Products/In Vitro Diagnostic/ Products/Molecular Biology Reagents/ Accessory Products
Product Highlights:
NextSeq 500/550 v2 sequencing reagent kits bring the power of a high-throughput sequencing system to the desktop, now with improved data quality and the highest yield of error-free reads. These kits offer:
The kits deliver powerful sequencing chemistries with as little as 10 minutes of hands-on time. Intuitive labeling and RFID-encoded reagents ensure compatibility with user-defined run configurations.
Ready-to-use cartridges redefine ease-of-use
Pre-configured reagent kits for the NextSeq Series Systems provide all the components needed for sequencing on the platform in 3 ready-to-use cartridges (reagent, flow cell, and buffer). The kits offer simplified cartridge loADIng with the bleach and dual-indexing primers already in the cartridge.
Simply load user-prepared library pools directly into the NextSeq reagent cartridge. The system automatically performs all steps necessary for template amplification and sequencing without user intervention.
Specifications:
Maximum Output | 120 Gb (300-cycle high output kit), 60 Gb (150-cycle high output kit), 39 Gb (300-cycle mid output kit), 30 Gb (75-cycle high output kit), 19.5 Gb (150-cycle mid output kit) |
Maximum Reads per Run | 400 million clusters (high output kits), 130 million clusters (mid output kits) |
Reagent Type | Paired-End Sequencing,Cluster Generation,Sequencing by Synthesis,Single-Read Sequencing |
System Compatibility | NextSeq 550,NextSeq 500 |
Technology | Sequencing |
上海易匯生物科技有限公司于17年正式銷售Illumina公司基因芯片、二代測(cè)序NGS測(cè)序儀及相關(guān)測(cè)序試劑盒等產(chǎn)品
咨詢illumina MiSeq測(cè)序試劑盒等產(chǎn)品歡迎您致電 上海易匯生物科技有限公司:1850 1609 238張經(jīng)理
Illumina公司,致力于新一代測(cè)序和芯片技術(shù)的生產(chǎn)與開發(fā),提供的產(chǎn)品與應(yīng)用資訊。Illumina公司創(chuàng)立于1998年4月,是遺傳變異和生物學(xué)功能分析領(lǐng)域的優(yōu)秀的產(chǎn)品、技術(shù)和服務(wù)供應(yīng)商。通過幫助客戶加快實(shí)現(xiàn)生物信息的采集、分析和應(yīng)用,來改善人類健康。
As a startup, Illumina aspired to transform human health. Our initial products enabled researchers to explore DNA at an entirely new scale, helping them create the first map of gene variations associated with health, disease, and drug response. Every breakthrough opened up a new world, and showed us how much further there is to go
While the rate of progress is accelerating exponentially, we are only beginning to understand the clinical significance of the genome. What causes a cancer cell to mutate? What is the origin of a puzzling disease? Is it possible to prevent the next outbreak? Or safeguard the world’s food supply? These are just a few of the challenges that inspire us to push the boundaries of our imagination
Today we are a global leader in genomics – an industry at the intersection of biology and technology. At the most fundamental level, we enable our customers to read and understand genetic variations. We strive to make our solutions increasingly simple, more accessible, and always reliable. As a result, discoveries that were unimaginable even a few years ago are now becoming routine – and are making their way into patient treatment.
We now have the ability to sequence at an unprecedented scale. Collectively, this will give us a much deeper understanding of genetics than ever before. We will begin to truly unlock the power of the genome. These advances will trigger a fundamental shift in healthcare and beyond. Medicine will continue to become more preventive and more precise. We will be healthier, longer. We have only just begun.
At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we strive to meet this challenge. Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics
Illumina 測(cè)序試劑盒 FC-404-2005
產(chǎn)品咨詢